UK markets closed

Cara Therapeutics, Inc. (0HTC.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
0.6759-0.0127 (-1.85%)
At close: 06:40PM BST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.70
52-week change 3-84.91%
S&P500 52-week change 321.23%
52-week high 35.8150
52-week low 30.5000
50-day moving average 30.6887
200-day moving average 31.8870

Share statistics

Avg vol (3-month) 318.63k
Avg vol (10-day) 327.96k
Shares outstanding 539.45M
Implied shares outstanding 6N/A
Float 839.36M
% held by insiders 114.58%
% held by institutions 145.49%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,085.45%

Management effectiveness

Return on assets (ttm)-49.29%
Return on equity (ttm)-109.80%

Income statement

Revenue (ttm)20.97M
Revenue per share (ttm)0.39
Quarterly revenue growth (yoy)-7.90%
Gross profit (ttm)N/A
EBITDA -121.24M
Net income avi to common (ttm)-118.51M
Diluted EPS (ttm)-1.8000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)100.76M
Total cash per share (mrq)1.84
Total debt (mrq)43.17M
Total debt/equity (mrq)75.62%
Current ratio (mrq)4.54
Book value per share (mrq)1.05

Cash flow statement

Operating cash flow (ttm)-92.08M
Levered free cash flow (ttm)-52.53M